Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection.
Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment …

Host-directed therapies are a relatively new and promising approach to treatment of
tuberculosis. Modulation of specific host immune pathways, including those that impact …

Towards host-directed therapies for tuberculosis | Nature Reviews Drug Discovery Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …

Treatment of tuberculosis (TB) remains challenging, with lengthy treatment durations and
complex drug regimens that are toxic and difficult to administer. Similar to the vast majority of …

The emergence and spread of drug-resistant strains of Mycobacterium tuberculosis is
worsening the global threat of tuberculosis (TB). There is a need and urgency for the …

Abstract Bacille Calmette-Guérin (BCG) is the only licenced tuberculosis (TB) vaccine, but
has limited efficacy against pulmonary TB disease development and modest protection …

Following infection with Mycobacterium tuberculosis, the causative agent of tuberculosis
(TB), most human hosts are able to contain the infection and avoid progression to active TB …

Abstract Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging
due to the virulence of the etiologic strains of Mycobacterium tuberculosis (M. tb), the …

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of
morbidity and mortality in humans worldwide. Currently, the standard treatment for TB …

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has co‐evolved with
the human immune system and utilizes multiple strategies to persist within infected cells, to …